ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Infectious diseases · Vaccine · 2026-06-17

Meta-analysis of post-licensure observational studies: recombinant zoster vaccine effectiveness against herpes zoster was 80.0% in immunocompetent and 64.3% in immunocompromised adults, 73.0% after four years; heterogeneity was substantial and subgroup data limited.

Meta-analysis
Mbinta et al. Effectiveness of recombinant zoster vaccine against herpes zoster and postherpetic neuralgia: a systematic review and meta-analysis of post-licensure observational studies
Rheumatology · Semin Arthritis Rheum · 2026-03-24

In 67 immunocompromised Sjögren's disease patients v 201 non-immunosuppressed controls, seroconversion after recombinant zoster vaccine was lower (90.6% v 99.5%; P<0.001) with lower titres; cellular responses were similar and no serious vaccine-related AEs occurred.

RCTn = 268
Pasoto et al. Lower magnitude of humoral response to recombinant herpes zoster vaccine in immunocompromised Sjögren's disease patients: evidence from a randomized double-blinded placebo-controlled trial

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.